If drugs can be designed or screened which reduce NeuroD1 expression to levels near those seen in the normal pituitary gland, such drugs could be vital in the treatment of aggressive neuroendocrine tumors or in the prevention of their reoccurrence. The gene discussed is NEUROD1; the disease is neuroendocrine neoplasm.